Cognitive Rehabilitation for People With Cognitive Covid19

Summary

Cognitive impairment is increasingly recognised as a major component of long Covid, and is estimated to be present in 25-75% of affected individuals. This impairment impacts quality of life and the loss of functional ability has major consequences for affected people, their families and the wider economy given people's difficulty in returning to work.

This study will focus on helping people recover from cognitive Covid. This will involve use of rehabilitation strategies aimed at improving function in those cognitive functions identified in Stage 1 as being most affected, and assessing the benefit of rehabilitation on quality of life and people's ability to return to everyday function. These strategies will be co-produced in collaboration with a group of people living with cognitive Covid. At the end of Stage 2 we will produce a freely available "Covid-19 Cognitive Recovery Guide" for affected people, their close contacts and clinicians.

In conclusion, cognitive impairment is frequently observed in long Covid but at present little is understood about its nature, or how it can be treated. The sheer scale of the CV19 pandemic makes this a top priority unmet need for healthcare worldwide. The aim of this study is to meet this need and to deliver a treatment plan for affected people which will help them return to normal life and working ability.

Conditions

• Long Covid19

Interventions

BEHAVIORAL

Cognitive rehabilitation

Set of restorative and compensatory strategies to rehabilitate cognitive function combined with emotional regulation techniques.

Sponsors & Collaborators

• Bangor University

  collaborator OTHER

• St George's University Hospitals NHS Foundation Trust

  collaborator OTHER

• University of Brighton

  collaborator OTHER

• University Hospital Southampton NHS Foundation Trust

  collaborator OTHER

• Greater Manchester Mental Health NHS Foundation Trust

  collaborator OTHER

• University College, London

  lead OTHER

Principal Investigators

• Dennis Chan, Dr · University College, London

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

30 Years

Max Age

60 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-02-14

Primary Completion

2024-07-31

Completion

2024-09-30

Countries

• United Kingdom

Study Locations